ID   FABI_ECOLI              Reviewed;         262 AA.
AC   P0AEK4; P29132;
DT   20-DEC-2005, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   15-MAR-2017, entry version 110.
DE   RecName: Full=Enoyl-[acyl-carrier-protein] reductase [NADH] FabI;
DE            Short=ENR;
DE            EC=1.3.1.9;
DE   AltName: Full=NADH-dependent enoyl-ACP reductase;
GN   Name=fabI; Synonyms=envM; OrderedLocusNames=b1288, JW1281;
OS   Escherichia coli (strain K12).
OC   Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacterales;
OC   Enterobacteriaceae; Escherichia.
OX   NCBI_TaxID=83333;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 2-31, AND
RP   MUTAGENESIS OF GLY-93.
RX   PubMed=1364817; DOI=10.1099/00221287-138-10-2093;
RA   Bergler H., Hoegenauer G., Turnowsky F.;
RT   "Sequences of the envM gene and of two mutated alleles in Escherichia
RT   coli.";
RL   J. Gen. Microbiol. 138:2093-2100(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=K12 / W3110 / ATCC 27325 / DSM 5911;
RX   PubMed=8075395; DOI=10.1007/BF00028873;
RA   Kater M.M., Koningstein G.M., Nijkamp H.J.J., Stuitje A.R.;
RT   "The use of a hybrid genetic system to study the functional
RT   relationship between prokaryotic and plant multi-enzyme fatty acid
RT   synthetase complexes.";
RL   Plant Mol. Biol. 25:771-790(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / W3110 / ATCC 27325 / DSM 5911;
RX   PubMed=9097039; DOI=10.1093/dnares/3.6.363;
RA   Aiba H., Baba T., Fujita K., Hayashi K., Inada T., Isono K., Itoh T.,
RA   Kasai H., Kashimoto K., Kimura S., Kitakawa M., Kitagawa M.,
RA   Makino K., Miki T., Mizobuchi K., Mori H., Mori T., Motomura K.,
RA   Nakade S., Nakamura Y., Nashimoto H., Nishio Y., Oshima T., Saito N.,
RA   Sampei G., Seki Y., Sivasundaram S., Tagami H., Takeda J.,
RA   Takemoto K., Takeuchi Y., Wada C., Yamamoto Y., Horiuchi T.;
RT   "A 570-kb DNA sequence of the Escherichia coli K-12 genome
RT   corresponding to the 28.0-40.1 min region on the linkage map.";
RL   DNA Res. 3:363-377(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RX   PubMed=9278503; DOI=10.1126/science.277.5331.1453;
RA   Blattner F.R., Plunkett G. III, Bloch C.A., Perna N.T., Burland V.,
RA   Riley M., Collado-Vides J., Glasner J.D., Rode C.K., Mayhew G.F.,
RA   Gregor J., Davis N.W., Kirkpatrick H.A., Goeden M.A., Rose D.J.,
RA   Mau B., Shao Y.;
RT   "The complete genome sequence of Escherichia coli K-12.";
RL   Science 277:1453-1462(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / W3110 / ATCC 27325 / DSM 5911;
RX   PubMed=16738553; DOI=10.1038/msb4100049;
RA   Hayashi K., Morooka N., Yamamoto Y., Fujita K., Isono K., Choi S.,
RA   Ohtsubo E., Baba T., Wanner B.L., Mori H., Horiuchi T.;
RT   "Highly accurate genome sequences of Escherichia coli K-12 strains
RT   MG1655 and W3110.";
RL   Mol. Syst. Biol. 2:E1-E5(2006).
RN   [6]
RP   PARTIAL PROTEIN SEQUENCE, FUNCTION AS AN ENOYL-ACP REDUCTASE,
RP   CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND ENZYME
RP   REGULATION.
RX   PubMed=8119879;
RA   Bergler H., Wallner P., Ebeling A., Leitinger B., Fuchsbichler S.,
RA   Aschauer H., Kollenz G., Hoegenauer G., Turnowsky F.;
RT   "Protein EnvM is the NADH-dependent enoyl-ACP reductase (FabI) of
RT   Escherichia coli.";
RL   J. Biol. Chem. 269:5493-5496(1994).
RN   [7]
RP   PROTEIN SEQUENCE OF 2-13.
RC   STRAIN=K12 / EMG2;
RX   PubMed=9298646; DOI=10.1002/elps.1150180807;
RA   Link A.J., Robison K., Church G.M.;
RT   "Comparing the predicted and observed properties of proteins encoded
RT   in the genome of Escherichia coli K-12.";
RL   Electrophoresis 18:1259-1313(1997).
RN   [8]
RP   PROTEIN SEQUENCE OF 2-12.
RC   STRAIN=K12 / W3110 / ATCC 27325 / DSM 5911;
RA   Frutiger S., Hughes G.J., Pasquali C., Hochstrasser D.F.;
RL   Submitted (FEB-1996) to UniProtKB.
RN   [9]
RP   FUNCTION IN FATTY ACID BIOSYNTHESIS.
RX   PubMed=7592873; DOI=10.1074/jbc.270.44.26538;
RA   Heath R.J., Rock C.O.;
RT   "Enoyl-acyl carrier protein reductase (fabI) plays a determinant role
RT   in completing cycles of fatty acid elongation in Escherichia coli.";
RL   J. Biol. Chem. 270:26538-26542(1995).
RN   [10]
RP   ENZYME REGULATION, AND MUTAGENESIS OF GLY-93; MET-159 AND PHE-203.
RX   PubMed=9707111; DOI=10.1038/28970;
RA   McMurry L.M., Oethinger M., Levy S.B.;
RT   "Triclosan targets lipid synthesis.";
RL   Nature 394:531-532(1998).
RN   [11]
RP   ENZYME REGULATION.
RX   PubMed=19959361; DOI=10.1016/j.bmcl.2009.11.042;
RA   Yao J., Zhang Q., Min J., He J., Yu Z.;
RT   "Novel enoyl-ACP reductase (FabI) potential inhibitors of Escherichia
RT   coli from Chinese medicine monomers.";
RL   Bioorg. Med. Chem. Lett. 20:56-59(2010).
RN   [12]
RP   FUNCTION IN BIOTIN BIOSYNTHESIS.
RX   PubMed=20693992; DOI=10.1038/nchembio.420;
RA   Lin S., Hanson R.E., Cronan J.E.;
RT   "Biotin synthesis begins by hijacking the fatty acid synthetic
RT   pathway.";
RL   Nat. Chem. Biol. 6:682-688(2010).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) IN COMPLEX WITH NAD AND
RP   INHIBITOR, ENZYME REGULATION, AND SUBUNIT.
RX   PubMed=8953047; DOI=10.1126/science.274.5295.2107;
RA   Baldock C., Rafferty J.B., Sedelnikova S.E., Baker P.J., Stuitje A.R.,
RA   Slabas A.R., Hawkes T.R., Rice D.W.;
RT   "A mechanism of drug action revealed by structural studies of enoyl
RT   reductase.";
RL   Science 274:2107-2110(1996).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) IN COMPLEX WITH NAD AND
RP   INHIBITOR, ENZYME REGULATION, AND SUBUNIT.
RX   PubMed=10493822; DOI=10.1021/bi9907779;
RA   Ward W.H., Holdgate G.A., Rowsell S., McLean E.G., Pauptit R.A.,
RA   Clayton E., Nichols W.W., Colls J.G., Minshull C.A., Jude D.A.,
RA   Mistry A., Timms D., Camble R., Hales N.J., Britton C.J., Taylor I.W.;
RT   "Kinetic and structural characteristics of the inhibition of enoyl
RT   (acyl carrier protein) reductase by triclosan.";
RL   Biochemistry 38:12514-12525(1999).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) IN COMPLEX WITH NAD AND
RP   INHIBITOR, ENZYME REGULATION, AND SUBUNIT.
RX   PubMed=10398587; DOI=10.1006/jmbi.1999.2907;
RA   Stewart M.J., Parikh S., Xiao G., Tonge P.J., Kisker C.;
RT   "Structural basis and mechanism of enoyl reductase inhibition by
RT   triclosan.";
RL   J. Mol. Biol. 290:859-865(1999).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) IN COMPLEX WITH NAD AND
RP   INHIBITOR.
RX   PubMed=10201369; DOI=10.1038/18803;
RA   Levy C.W., Roujeinikova A., Sedelnikova S., Baker P.J., Stuitje A.R.,
RA   Slabas A.R., Rice D.W., Rafferty J.B.;
RT   "Molecular basis of triclosan activity.";
RL   Nature 398:383-384(1999).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) IN COMPLEX WITH NAD AND
RP   INHIBITOR.
RX   PubMed=10595560; DOI=10.1110/ps.8.11.2529;
RA   Qiu X., Janson C.A., Court R.I., Smyth M.G., Payne D.J.,
RA   Abdel-Meguid S.S.;
RT   "Molecular basis for triclosan activity involves a flipping loop in
RT   the active site.";
RL   Protein Sci. 8:2529-2532(1999).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) IN COMPLEX WITH NAD AND
RP   INHIBITOR, AND ENZYME REGULATION.
RX   PubMed=11514139; DOI=10.1016/S0960-894X(01)00404-8;
RA   Heerding D.A., Chan G., DeWolf W.E., Fosberry A.P., Janson C.A.,
RA   Jaworski D.D., McManus E., Miller W.H., Moore T.D., Payne D.J.,
RA   Qiu X., Rittenhouse S.F., Slater-Radosti C., Smith W., Takata D.T.,
RA   Vaidya K.S., Yuan C.C., Huffman W.F.;
RT   "1,4-Disubstituted imidazoles are potential antibacterial agents
RT   functioning as inhibitors of enoyl acyl carrier protein reductase
RT   (FabI).";
RL   Bioorg. Med. Chem. Lett. 11:2061-2065(2001).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) IN COMPLEX WITH NAD AND
RP   INHIBITOR, AND ENZYME REGULATION.
RX   PubMed=12109908; DOI=10.1021/jm020050+;
RA   Miller W.H., Seefeld M.A., Newlander K.A., Uzinskas I.N.,
RA   Burgess W.J., Heerding D.A., Yuan C.C., Head M.S., Payne D.J.,
RA   Rittenhouse S.F., Moore T.D., Pearson S.C., Berry V., DeWolf W.E. Jr.,
RA   Keller P.M., Polizzi B.J., Qiu X., Janson C.A., Huffman W.F.;
RT   "Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP
RT   reductase (FabI).";
RL   J. Med. Chem. 45:3246-3256(2002).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.33 ANGSTROMS) IN COMPLEX WITH NAD AND
RP   INHIBITOR, AND ENZYME REGULATION.
RX   PubMed=12699381; DOI=10.1021/jm0204035;
RA   Seefeld M.A., Miller W.H., Newlander K.A., Burgess W.J.,
RA   DeWolf W.E. Jr., Elkins P.A., Head M.S., Jakas D.R., Janson C.A.,
RA   Keller P.M., Manley P.J., Moore T.D., Payne D.J., Pearson S.,
RA   Polizzi B.J., Qiu X., Rittenhouse S.F., Uzinskas I.N., Wallis N.G.,
RA   Huffman W.F.;
RT   "Indole naphthyridinones as inhibitors of bacterial enoyl-ACP
RT   reductases FabI and FabK.";
RL   J. Med. Chem. 46:1627-1635(2003).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS), MUTAGENESIS OF TYR-146;
RP   TYR-156; LYS-201; ARG-204 AND LYS-205, AND BIOPHYSICOCHEMICAL
RP   PROPERTIES.
RX   PubMed=17012233; DOI=10.1074/jbc.M608758200;
RA   Rafi S., Novichenok P., Kolappan S., Zhang X., Stratton C.F.,
RA   Rawat R., Kisker C., Simmerling C., Tonge P.J.;
RT   "Structure of acyl carrier protein bound to FabI, the FASII enoyl
RT   reductase from Escherichia coli.";
RL   J. Biol. Chem. 281:39285-39293(2006).
CC   -!- FUNCTION: Catalyzes the reduction of a carbon-carbon double bond
CC       in an enoyl moiety that is covalently linked to an acyl carrier
CC       protein (ACP). Involved in the elongation cycle of fatty acid
CC       which are used in the lipid metabolism and in the biotin
CC       biosynthesis. {ECO:0000269|PubMed:20693992,
CC       ECO:0000269|PubMed:7592873, ECO:0000269|PubMed:8119879}.
CC   -!- CATALYTIC ACTIVITY: An acyl-[acyl-carrier protein] + NAD(+) = a
CC       trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH.
CC       {ECO:0000269|PubMed:8119879}.
CC   -!- ENZYME REGULATION: Inhibited by diazaborines, triclosan (5-chloro-
CC       2-2,4-dichlorophenoxyphenol), 1,4-disubstituted imidazoles, 1,4-
CC       benzodiazepine derivatives, naphthyridinone derivatives, luteolin
CC       and curcumin. {ECO:0000269|PubMed:10398587,
CC       ECO:0000269|PubMed:10493822, ECO:0000269|PubMed:11514139,
CC       ECO:0000269|PubMed:12109908, ECO:0000269|PubMed:12699381,
CC       ECO:0000269|PubMed:19959361, ECO:0000269|PubMed:8119879,
CC       ECO:0000269|PubMed:8953047, ECO:0000269|PubMed:9707111}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=3.3 uM for trans-2-dodecenoyl-ACP (DD-ACP)(at 25 degrees
CC         Celsius and pH 8) {ECO:0000269|PubMed:17012233,
CC         ECO:0000269|PubMed:8119879};
CC         KM=22 uM for crotonyl-ACP (at 30 degrees Celsius and pH 7.5)
CC         {ECO:0000269|PubMed:17012233, ECO:0000269|PubMed:8119879};
CC         KM=24 uM for trans-2-dodecenoyl-CoA (DD-CoA)(at 25 degrees
CC         Celsius and pH 8) {ECO:0000269|PubMed:17012233,
CC         ECO:0000269|PubMed:8119879};
CC         KM=2700 uM for crotonyl-CoA (at 30 degrees Celsius and pH 7.5)
CC         {ECO:0000269|PubMed:17012233, ECO:0000269|PubMed:8119879};
CC   -!- PATHWAY: Lipid metabolism; fatty acid biosynthesis.
CC   -!- PATHWAY: Cofactor biosynthesis; biotin biosynthesis.
CC   -!- SUBUNIT: Homotetramer. {ECO:0000269|PubMed:10201369,
CC       ECO:0000269|PubMed:10398587, ECO:0000269|PubMed:10493822,
CC       ECO:0000269|PubMed:10595560, ECO:0000269|PubMed:11514139,
CC       ECO:0000269|PubMed:12109908, ECO:0000269|PubMed:12699381,
CC       ECO:0000269|PubMed:8953047}.
CC   -!- MISCELLANEOUS: The antibiotic diazaborine interferes with the
CC       activity by binding to the protein and NAD.
CC   -!- SIMILARITY: Belongs to the short-chain dehydrogenases/reductases
CC       (SDR) family. FabI subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M97219; AAA17755.1; -; Unassigned_DNA.
DR   EMBL; X78733; CAA55381.1; -; Genomic_DNA.
DR   EMBL; U00096; AAC74370.1; -; Genomic_DNA.
DR   EMBL; AP009048; BAA14841.1; -; Genomic_DNA.
DR   PIR; S48029; S48029.
DR   RefSeq; NP_415804.1; NC_000913.3.
DR   RefSeq; WP_000506490.1; NZ_LN832404.1.
DR   PDB; 1C14; X-ray; 2.00 A; A/B=1-262.
DR   PDB; 1D8A; X-ray; 2.20 A; A/B=2-262.
DR   PDB; 1DFG; X-ray; 2.50 A; A/B=2-262.
DR   PDB; 1DFH; X-ray; 2.20 A; A/B=2-262.
DR   PDB; 1DFI; X-ray; 2.09 A; A/B/C/D=2-262.
DR   PDB; 1I2Z; X-ray; 2.80 A; A/B=1-262.
DR   PDB; 1I30; X-ray; 2.40 A; A/B=1-262.
DR   PDB; 1LX6; X-ray; 2.40 A; A/B=1-262.
DR   PDB; 1LXC; X-ray; 2.40 A; A/B=1-262.
DR   PDB; 1MFP; X-ray; 2.33 A; A/B=1-262.
DR   PDB; 1QG6; X-ray; 1.90 A; A/B/C/D=2-262.
DR   PDB; 1QSG; X-ray; 1.75 A; A/B/C/D/E/F/G/H=1-262.
DR   PDB; 2FHS; X-ray; 2.70 A; A/B=1-262.
DR   PDB; 3PJD; X-ray; 2.50 A; A/B=1-262.
DR   PDB; 3PJE; X-ray; 2.50 A; A/B=1-262.
DR   PDB; 3PJF; X-ray; 1.90 A; A/B=1-262.
DR   PDB; 4JQC; X-ray; 2.80 A; A/B=1-262.
DR   PDB; 4JX8; X-ray; 3.20 A; A/B=1-262.
DR   PDB; 5CFZ; X-ray; 1.97 A; A/B=1-262.
DR   PDB; 5CG1; X-ray; 2.07 A; A/B=1-262.
DR   PDB; 5CG2; X-ray; 2.11 A; A/B=1-262.
DR   PDBsum; 1C14; -.
DR   PDBsum; 1D8A; -.
DR   PDBsum; 1DFG; -.
DR   PDBsum; 1DFH; -.
DR   PDBsum; 1DFI; -.
DR   PDBsum; 1I2Z; -.
DR   PDBsum; 1I30; -.
DR   PDBsum; 1LX6; -.
DR   PDBsum; 1LXC; -.
DR   PDBsum; 1MFP; -.
DR   PDBsum; 1QG6; -.
DR   PDBsum; 1QSG; -.
DR   PDBsum; 2FHS; -.
DR   PDBsum; 3PJD; -.
DR   PDBsum; 3PJE; -.
DR   PDBsum; 3PJF; -.
DR   PDBsum; 4JQC; -.
DR   PDBsum; 4JX8; -.
DR   PDBsum; 5CFZ; -.
DR   PDBsum; 5CG1; -.
DR   PDBsum; 5CG2; -.
DR   ProteinModelPortal; P0AEK4; -.
DR   SMR; P0AEK4; -.
DR   BioGrid; 4260135; 284.
DR   DIP; DIP-31867N; -.
DR   IntAct; P0AEK4; 12.
DR   MINT; MINT-1251203; -.
DR   STRING; 511145.b1288; -.
DR   BindingDB; P0AEK4; -.
DR   ChEMBL; CHEMBL1857; -.
DR   DrugBank; DB01865; 3-(6-Aminopyridin-3-Yl)-N-Methyl-N-[(1-Methyl-1h-Indol-2-Yl)Methyl]Acrylamide.
DR   DrugBank; DB03534; 3-[(Acetyl-Methyl-Amino)-Methyl]-4-Amino-N-Methyl-N-(1-Methyl-1h-Indol-2-Ylmethyl)-Benzamide.
DR   DrugBank; DB03030; 4-(2-Thienyl)-1-(4-Methylbenzyl)-1h-Imidazole.
DR   DrugBank; DB02379; Beta-D-Glucose.
DR   DrugBank; DB01691; Indole Naphthyridinone.
DR   DrugBank; DB08604; Triclosan.
DR   SWISS-2DPAGE; P0AEK4; -.
DR   EPD; P0AEK4; -.
DR   PaxDb; P0AEK4; -.
DR   PRIDE; P0AEK4; -.
DR   EnsemblBacteria; AAC74370; AAC74370; b1288.
DR   EnsemblBacteria; BAA14841; BAA14841; BAA14841.
DR   GeneID; 945870; -.
DR   KEGG; ecj:JW1281; -.
DR   KEGG; eco:b1288; -.
DR   PATRIC; 32117844; VBIEscCol129921_1342.
DR   EchoBASE; EB1490; -.
DR   EcoGene; EG11528; fabI.
DR   eggNOG; ENOG4105CSJ; Bacteria.
DR   eggNOG; COG0623; LUCA.
DR   InParanoid; P0AEK4; -.
DR   KO; K00208; -.
DR   OMA; SACKREG; -.
DR   PhylomeDB; P0AEK4; -.
DR   BioCyc; EcoCyc:ENOYL-ACP-REDUCT-NADH-MONOMER; -.
DR   BioCyc; MetaCyc:ENOYL-ACP-REDUCT-NADH-MONOMER; -.
DR   BRENDA; 1.3.1.9; 2026.
DR   SABIO-RK; P0AEK4; -.
DR   UniPathway; UPA00078; -.
DR   UniPathway; UPA00094; -.
DR   EvolutionaryTrace; P0AEK4; -.
DR   PRO; PR:P0AEK4; -.
DR   Proteomes; UP000000318; Chromosome.
DR   Proteomes; UP000000625; Chromosome.
DR   GO; GO:0005829; C:cytosol; IDA:EcoCyc.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0004318; F:enoyl-[acyl-carrier-protein] reductase (NADH) activity; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IDA:EcoCyc.
DR   GO; GO:0009102; P:biotin biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0030497; P:fatty acid elongation; IDA:UniProtKB.
DR   GO; GO:0008610; P:lipid biosynthetic process; IDA:EcoCyc.
DR   GO; GO:0051289; P:protein homotetramerization; IDA:UniProtKB.
DR   GO; GO:0046677; P:response to antibiotic; IEA:UniProtKB-KW.
DR   Gene3D; 3.40.50.720; -; 1.
DR   InterPro; IPR014358; Enoyl-ACP_Rdtase_NADH.
DR   InterPro; IPR016040; NAD(P)-bd_dom.
DR   InterPro; IPR002347; SDR_fam.
DR   PANTHER; PTHR43159:SF2; PTHR43159:SF2; 1.
DR   PIRSF; PIRSF000094; Enoyl-ACP_rdct; 1.
DR   PRINTS; PR00081; GDHRDH.
DR   SUPFAM; SSF51735; SSF51735; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Antibiotic resistance; Complete proteome;
KW   Direct protein sequencing; Fatty acid biosynthesis;
KW   Fatty acid metabolism; Lipid biosynthesis; Lipid metabolism; NAD;
KW   Oxidoreductase; Reference proteome.
FT   INIT_MET      1      1       Removed. {ECO:0000269|PubMed:1364817,
FT                                ECO:0000269|PubMed:9298646,
FT                                ECO:0000269|Ref.8}.
FT   CHAIN         2    262       Enoyl-[acyl-carrier-protein] reductase
FT                                [NADH] FabI.
FT                                /FTId=PRO_0000054899.
FT   NP_BIND      19     20       NAD. {ECO:0000269|PubMed:10201369,
FT                                ECO:0000269|PubMed:10398587,
FT                                ECO:0000269|PubMed:10493822,
FT                                ECO:0000269|PubMed:10595560,
FT                                ECO:0000269|PubMed:11514139,
FT                                ECO:0000269|PubMed:12109908,
FT                                ECO:0000269|PubMed:12699381,
FT                                ECO:0000269|PubMed:8953047}.
FT   NP_BIND      64     65       NAD. {ECO:0000269|PubMed:10201369,
FT                                ECO:0000269|PubMed:10398587,
FT                                ECO:0000269|PubMed:10493822,
FT                                ECO:0000269|PubMed:10595560,
FT                                ECO:0000269|PubMed:11514139,
FT                                ECO:0000269|PubMed:12109908,
FT                                ECO:0000269|PubMed:12699381,
FT                                ECO:0000269|PubMed:8953047}.
FT   NP_BIND     192    196       NAD. {ECO:0000269|PubMed:10201369,
FT                                ECO:0000269|PubMed:10398587,
FT                                ECO:0000269|PubMed:10493822,
FT                                ECO:0000269|PubMed:10595560,
FT                                ECO:0000269|PubMed:11514139,
FT                                ECO:0000269|PubMed:12109908,
FT                                ECO:0000269|PubMed:12699381,
FT                                ECO:0000269|PubMed:8953047}.
FT   ACT_SITE    146    146       Proton acceptor. {ECO:0000250}.
FT   ACT_SITE    156    156       Proton acceptor. {ECO:0000250}.
FT   BINDING      13     13       NAD; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:10201369,
FT                                ECO:0000269|PubMed:10398587,
FT                                ECO:0000269|PubMed:10493822,
FT                                ECO:0000269|PubMed:10595560,
FT                                ECO:0000269|PubMed:11514139,
FT                                ECO:0000269|PubMed:12109908,
FT                                ECO:0000269|PubMed:12699381,
FT                                ECO:0000269|PubMed:8953047}.
FT   BINDING      40     40       NAD. {ECO:0000269|PubMed:10201369,
FT                                ECO:0000269|PubMed:10398587,
FT                                ECO:0000269|PubMed:10493822,
FT                                ECO:0000269|PubMed:10595560,
FT                                ECO:0000269|PubMed:11514139,
FT                                ECO:0000269|PubMed:12109908,
FT                                ECO:0000269|PubMed:12699381,
FT                                ECO:0000269|PubMed:8953047}.
FT   BINDING      92     92       NAD; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:10201369,
FT                                ECO:0000269|PubMed:10398587,
FT                                ECO:0000269|PubMed:10493822,
FT                                ECO:0000269|PubMed:10595560,
FT                                ECO:0000269|PubMed:11514139,
FT                                ECO:0000269|PubMed:12109908,
FT                                ECO:0000269|PubMed:12699381,
FT                                ECO:0000269|PubMed:8953047}.
FT   BINDING      95     95       Substrate; via amide nitrogen and
FT                                carbonyl oxygen.
FT   BINDING     163    163       NAD. {ECO:0000269|PubMed:10201369,
FT                                ECO:0000269|PubMed:10398587,
FT                                ECO:0000269|PubMed:10493822,
FT                                ECO:0000269|PubMed:10595560,
FT                                ECO:0000269|PubMed:11514139,
FT                                ECO:0000269|PubMed:12109908,
FT                                ECO:0000269|PubMed:12699381,
FT                                ECO:0000269|PubMed:8953047}.
FT   SITE        201    201       Involved in acyl-ACP binding.
FT   SITE        204    204       Involved in acyl-ACP binding.
FT   SITE        205    205       Involved in acyl-ACP binding.
FT   MUTAGEN      93     93       G->S: Diazaborine resistance.
FT                                {ECO:0000269|PubMed:1364817,
FT                                ECO:0000269|PubMed:9707111}.
FT   MUTAGEN      93     93       G->V: Triclosan resistance.
FT                                {ECO:0000269|PubMed:1364817,
FT                                ECO:0000269|PubMed:9707111}.
FT   MUTAGEN     146    146       Y->F: Large impact on catalysis, with
FT                                kcat and kcat/Km for DD-ACP decreasing by
FT                                around 50-fold compared with wild-type.
FT                                {ECO:0000269|PubMed:17012233}.
FT   MUTAGEN     156    156       Y->F: No effect on substrate reduction.
FT                                {ECO:0000269|PubMed:17012233}.
FT   MUTAGEN     159    159       M->T: Triclosan resistance.
FT                                {ECO:0000269|PubMed:9707111}.
FT   MUTAGEN     201    201       K->A: No effect on substrate reduction.
FT                                {ECO:0000269|PubMed:17012233}.
FT   MUTAGEN     201    201       K->E: Little activity toward DD-CoA and
FT                                DD-ACP. {ECO:0000269|PubMed:17012233}.
FT   MUTAGEN     203    203       F->L: Triclosan resistance.
FT                                {ECO:0000269|PubMed:9707111}.
FT   MUTAGEN     204    204       R->A: No effect on substrate reduction.
FT                                {ECO:0000269|PubMed:17012233}.
FT   MUTAGEN     204    204       R->E: Causes a further reduction in
FT                                kcat/Km for reduction of DD-ACP without
FT                                affecting kcat/Km for the DD-CoA
FT                                substrate. {ECO:0000269|PubMed:17012233}.
FT   MUTAGEN     205    205       K->A: No effect on substrate reduction.
FT                                {ECO:0000269|PubMed:17012233}.
FT   MUTAGEN     205    205       K->E: Causes a further reduction in
FT                                kcat/Km for reduction of DD-ACP without
FT                                affecting kcat/Km for the DD-CoA
FT                                substrate. Has a larger impact on
FT                                substrate reduction.
FT                                {ECO:0000269|PubMed:17012233}.
FT   MUTAGEN     241    241       S->F: Produces temperature-sensitive
FT                                phenotype.
FT   TURN          3      6       {ECO:0000244|PDB:1QSG}.
FT   STRAND        8     11       {ECO:0000244|PDB:1QSG}.
FT   STRAND       16     19       {ECO:0000244|PDB:1DFI}.
FT   HELIX        20     30       {ECO:0000244|PDB:1QSG}.
FT   STRAND       34     41       {ECO:0000244|PDB:1QSG}.
FT   TURN         42     44       {ECO:0000244|PDB:1QSG}.
FT   HELIX        45     54       {ECO:0000244|PDB:1QSG}.
FT   STRAND       60     62       {ECO:0000244|PDB:1QSG}.
FT   HELIX        68     79       {ECO:0000244|PDB:1QSG}.
FT   STRAND       83     90       {ECO:0000244|PDB:1QSG}.
FT   HELIX        97    100       {ECO:0000244|PDB:1QSG}.
FT   STRAND      101    103       {ECO:0000244|PDB:4JX8}.
FT   HELIX       104    107       {ECO:0000244|PDB:1QSG}.
FT   HELIX       110    120       {ECO:0000244|PDB:1QSG}.
FT   HELIX       122    131       {ECO:0000244|PDB:1QSG}.
FT   HELIX       132    134       {ECO:0000244|PDB:1QSG}.
FT   STRAND      135    145       {ECO:0000244|PDB:1QSG}.
FT   HELIX       147    149       {ECO:0000244|PDB:1QSG}.
FT   TURN        154    157       {ECO:0000244|PDB:1QSG}.
FT   HELIX       158    177       {ECO:0000244|PDB:1QSG}.
FT   TURN        178    181       {ECO:0000244|PDB:1QSG}.
FT   STRAND      182    189       {ECO:0000244|PDB:1QSG}.
FT   HELIX       197    199       {ECO:0000244|PDB:1QSG}.
FT   STRAND      200    202       {ECO:0000244|PDB:1MFP}.
FT   HELIX       203    213       {ECO:0000244|PDB:1QSG}.
FT   HELIX       222    232       {ECO:0000244|PDB:1QSG}.
FT   HELIX       235    237       {ECO:0000244|PDB:1QSG}.
FT   STRAND      244    248       {ECO:0000244|PDB:1QSG}.
FT   HELIX       251    253       {ECO:0000244|PDB:1QSG}.
SQ   SEQUENCE   262 AA;  27864 MW;  436A89AF349D1866 CRC64;
     MGFLSGKRIL VTGVASKLSI AYGIAQAMHR EGAELAFTYQ NDKLKGRVEE FAAQLGSDIV
     LQCDVAEDAS IDTMFAELGK VWPKFDGFVH SIGFAPGDQL DGDYVNAVTR EGFKIAHDIS
     SYSFVAMAKA CRSMLNPGSA LLTLSYLGAE RAIPNYNVMG LAKASLEANV RYMANAMGPE
     GVRVNAISAG PIRTLAASGI KDFRKMLAHC EAVTPIRRTV TIEDVGNSAA FLCSDLSAGI
     SGEVVHVDGG FSIAAMNELE LK
//
